Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer

被引:27
|
作者
Monge, A
Jagla, M
Lapouge, G
Sasorith, S
Cruchant, M
Wurtz, JM
Jacqmin, D
Bergerat, JP
Céraline, J
机构
[1] Univ Strasbourg 1, Lab Cancerol Expt & Radiobiol, EA 3430, IRCAD, F-67091 Strasbourg, France
[2] IGBMC, Dept Biol & Genom Struct, Illkirch Graffenstaden, France
[3] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France
[4] Hop Univ Strasbourg, Serv Chirurg Urol, Strasbourg, France
关键词
androgen receptor; hormone-refractory prostate cancer; mutation; DNA binding specificity; transcriptional activity;
D O I
10.1007/s00018-005-5471-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Missense mutations in the androgen receptor (AR) contribute to the failure of hormonal therapy for prostate cancer (PCa), but the underlying molecular bases remain uncharacterized. Here, we describe a new AR variant found in a hormone-refractory metastatic PCa, in which threonine 575 in the DNA binding domain, and threonine 877 in the ligand-binding domain, were both replaced by an alanine. Using gene reporter assays, we demonstrate that the T575A mutation weakened transcriptional activity from promoters containing AR-spe-cific responsive elements, while activity from promoters with AR-non-specific elements was enhanced. Data from gel shift experiments revealed a preferential binding of the T575A mutant to AR-non-specific motifs. We demonstrate that the two mutations T575A and T877A cooperate to confer new functional properties on the AR, and that the mutant AR functions simultaneously as a promiscuous AR due to the T877A mutation, and an unfaithful AR due to the T575A mutation.
引用
收藏
页码:487 / 497
页数:11
相关论文
共 50 条
  • [21] Therapeutic options for hormone-refractory prostate cancer
    Miller, K.
    Boergermann, C.
    Thueroff, J.
    Albers, P.
    Wirth, M.
    UROLOGE, 2006, 45 (05): : 580 - +
  • [22] Treatment options for hormone-refractory prostate cancer
    Heidenreich, A
    Ohlmann, CH
    UROLOGE, 2005, 44 (11): : 1303 - +
  • [23] Therapeutic options for hormone-refractory prostate cancer
    Miller K.
    Börgermann C.
    Thüroff J.
    Albers P.
    Wirth M.
    Der Urologe, 2006, 45 (5): : 580 - 585
  • [24] Chemotherapy for the treatment of hormone-refractory prostate cancer
    Petrylak, DP
    EUROPEAN UROLOGY SUPPLEMENTS, 2002, 1 (02) : 15 - 23
  • [25] The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways
    Edwards, J
    Bartlett, JMS
    BJU INTERNATIONAL, 2005, 95 (09) : 1327 - 1335
  • [26] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Bellmunt, Joaquim
    Carles, Joan
    Albanell, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (02) : 82 - 85
  • [27] The role of urologists in the management of hormone-refractory prostate cancer
    Pummer, K
    EUROPEAN UROLOGY SUPPLEMENTS, 2002, 1 (02) : 24 - 28
  • [28] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Joaquim Bellmunt
    Joan Carles
    Joan Albanell
    Clinical and Translational Oncology, 2009, 11 : 82 - 85
  • [29] Which drug combination for hormone-refractory prostate cancer
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (04) : 667 - 670
  • [30] Radiotherapy for localized hormone-refractory prostate cancer in Japan
    Nakamura, K
    Teshima, T
    Takahashi, Y
    Imai, A
    Koizumi, M
    Mitsuhashi, N
    Shioyama, Y
    Inoue, T
    ANTICANCER RESEARCH, 2004, 24 (5B) : 3141 - 3145